Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Price competition and reimbursement of biosimilar granulocyte-colony stimulating factor in Hungary.

Hornyák L, Nagy Z, Ilku L, Tálos Z, Endrei D, Ágoston I, Csákvári T, Danku N, Répásy B, Boncz I.

Expert Rev Pharmacoecon Outcomes Res. 2019 Feb 14. doi: 10.1080/14737167.2019.1582334. [Epub ahead of print]

PMID:
30763134
2.

Commentary: Nuclear dynamics of the Set1C subunit Spp1 prepares meiotic recombination sites for break formation.

Fillér C, Hornyák L, Roszik J.

Front Genet. 2018 Oct 23;9:496. doi: 10.3389/fgene.2018.00496. eCollection 2018. No abstract available.

3.

The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy.

Hornyák L, Dobos N, Koncz G, Karányi Z, Páll D, Szabó Z, Halmos G, Székvölgyi L.

Front Immunol. 2018 Jan 31;9:151. doi: 10.3389/fimmu.2018.00151. eCollection 2018. Review.

4.

Multi-endpoint biological monitoring in combined, carcinogenic occupational exposures.

Szendi K, Hornyák L, Varga C.

Int J Environ Health Res. 2017 Oct;27(5):323-331. doi: 10.1080/09603123.2017.1339783. Epub 2017 Jun 14.

PMID:
28612659
5.

[The effect of generic price competition on drug consumption and health insurance pharmaceutical expenditures in Hungary].

Répásy B, Endrei D, Zemplényi A, Agoston I, Hornyák L, Nagy Z, Csákvári T, Vajda R, Boncz Imre.

Acta Pharm Hung. 2015;85(3):83-8. Hungarian.

PMID:
26642646
6.

Experiences With Price Competition Of Biosimilar Drugs In Hungary In Case Of Erythropoietin Products.

Nagy Z, Hornyák L, Tálos Z, Endrei D, Ágoston I, Csákvári T, Boncz I.

Value Health. 2015 Nov;18(7):A513. doi: 10.1016/j.jval.2015.09.1485. Epub 2015 Oct 20. No abstract available.

7.

Experiences with Price Competition of Biosimilar Drugs In Hungary in Case of Colony-Stimulating Factor Products.

Hornyák L, Nagy Z, Tálos Z, Endrei D, Ágoston I, Csákvári T, Boncz I.

Value Health. 2015 Nov;18(7):A477. doi: 10.1016/j.jval.2015.09.1285. Epub 2015 Oct 20. No abstract available.

8.

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.

Pivot X, Manikhas A, Żurawski B, Chmielowska E, Karaszewska B, Allerton R, Chan S, Fabi A, Bidoli P, Gori S, Ciruelos E, Dank M, Hornyak L, Margolin S, Nusch A, Parikh R, Nagi F, DeSilvio M, Santillana S, Swaby RF, Semiglazov V.

J Clin Oncol. 2015 May 10;33(14):1564-73. doi: 10.1200/JCO.2014.57.1794. Epub 2015 Jan 20.

PMID:
25605838
9.

Experiences With Price Competition of Biosimilar Drugs in Hungary.

Hornyák L, Nagy Z, Tálos Z, Ágoston I, Endrei D, Csákvári T, Boncz I.

Value Health. 2014 Nov;17(7):A418. doi: 10.1016/j.jval.2014.08.1018. Epub 2014 Oct 26. No abstract available.

10.

[Experiences with price competition of biosimilar drugs in Hungary].

Hornyák L, Nagy Z, Tálos Z, Endrei D, Ágoston I, Csákvári T, Boncz I.

Acta Pharm Hung. 2014;84(2):83-7. Hungarian.

PMID:
25167704
11.

HE4--a novel promising serum marker in the diagnosis of ovarian carcinoma.

Langmár Z, Németh M, Vleskó G, Király M, Hornyák L, Bösze P.

Eur J Gynaecol Oncol. 2011;32(6):605-10. Review.

PMID:
22335019
12.

Renal capsule-parathymic lymph node complex: a new in vivo metastatic model in rats.

Trencsenyi G, Kertai P, Bako F, Hunyadi J, Marian T, Hargitai Z, Pocsi I, Muranyi E, Hornyak L, Banfalvi G.

Anticancer Res. 2009 Jun;29(6):2121-6.

Supplemental Content

Loading ...
Support Center